Cargando…

Correction: Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner

Detalles Bibliográficos
Autores principales:	Yu, Feng, Li, Lili, Zhang, Mengwen, Sun, Shanshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691008/ https://www.ncbi.nlm.nih.gov/pubmed/38041002 http://dx.doi.org/10.1186/s12885-023-11676-7

Ejemplares similares

Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner
por: Yu, Feng, et al.
Publicado: (2023)

Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
por: Nie, Lei, et al.
Publicado: (2020)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
Publicado: (2020)

Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
por: Gijsen, Merel, et al.
Publicado: (2016)

Correction to: AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer
por: Al-Zahrani, Khalid N., et al.
Publicado: (2021)

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
por: Nie, Lei, et al.
Publicado: (2019)

Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2013)

Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2020)

Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer
por: Mirzaei, Sepideh, et al.
Publicado: (2022)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Correction: Involvement of CXCR4 Chemokine Receptor in Metastastic HER2-Positive Esophageal Cancer
por: Gros, Stephanie J., et al.
Publicado: (2013)

Correction: Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height
por: Tatton-Brown, Katrina, et al.
Publicado: (2018)

Correction: Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells
por: Vanderhoeven, Fiorella, et al.
Publicado: (2023)

Correction: Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
por: Zhang, Jinghui, et al.
Publicado: (2023)

Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
por: Martínez-Laperche, C., et al.
Publicado: (2022)

Correction: Lack of a site-specific phosphorylation of Presenilin 1 disrupts microglial gene networks and progenitors during development
por: Ledo, Jose Henrique, et al.
Publicado: (2021)

Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
por: Kawano, Satoshi, et al.
Publicado: (2017)

Correction: p63 suppresses the ability of pregnancy-identified mammary epithelial cells (PIMECs) to drive HER2-positive breast cancer
por: Eyermann, Christopher E., et al.
Publicado: (2021)

Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
por: Hu, Zexi, et al.
Publicado: (2018)

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2‑positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Correction: Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016)
por: Tang, Monica, et al.
Publicado: (2020)

Correction: CDKN1C (p57(KIP2)) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells
por: Yang, Xiaojing, et al.
Publicado: (2009)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Correction: Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells
por: Ma, Jui-Wen, et al.
Publicado: (2019)

Correction: Induction of phenotypic changes in HER2-postive breast cancer cells in vivo and in vitro
por: Frank-Kamenetskii, Anastasia, et al.
Publicado: (2023)

Correction to: Co-relation with novel phosphorylation sites of IκBα and necroptosis in breast cancer cells
por: Choi, Sung Hoon, et al.
Publicado: (2021)

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina S. J., et al.
Publicado: (2023)

Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer
por: Gori, Stefania, et al.
Publicado: (2015)

Correction: Long non-coding RNA HoxA-AS3 interacts with EZH2 to regulate lineage commitment of mesenchymal stem cells
por: Zhu, Xin-Xing, et al.
Publicado: (2018)

Correction to: EZH2 promotes the expression of LPA1 by mediating microRNA-139 promoter methylation to accelerate the development of ovarian cancer
por: Wu, Dongbo, et al.
Publicado: (2021)

Author Correction: Phosphorylated HBO1 at UV irradiated sites is essential for nucleotide excision repair
por: Niida, Hiroyuki, et al.
Publicado: (2018)

Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401
por: Serwotka-Suszczak, Anna M., et al.
Publicado: (2018)

Correction: Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression
por: Yu, Junhui, et al.
Publicado: (2023)

EZH2 expression in invasive lobular carcinoma of the breast
por: Roh, SiGyun, et al.
Publicado: (2013)

Correction: PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer
por: Yang, Tingting, et al.
Publicado: (2019)

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
por: Goldstein, Lori J., et al.
Publicado: (2020)

Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Correction: HER2 as a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy
por: Ma, Juan, et al.
Publicado: (2013)

PYK2 promotes HER2-positive breast cancer invasion
por: Al-Juboori, Shaymaa IK., et al.
Publicado: (2019)

Author Correction: Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes
por: Maoz, Myriam, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4ur3g6ohrp2ekkpjmam1nagibv